{
    "clinical_study": {
        "@rank": "48548", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Treatment A: Florastor\u00ae 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca\u00ae 100 mg three times per day from Day 3 to Day 16.\nFor Period 2, subjects will receive the alternate dosing regimen."
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "Treatment B: Florastor\u00ae 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca\u00ae 100 mg three times per day from Day 3 to Day 16.\nFor Period 2, subjects will receive the alternate dosing regimen."
            }
        ], 
        "brief_summary": {
            "textblock": "Cross-over, tolerability study with healthy subjects taking Zavesca in combination with\n      Florastor. Forty-two subjects will be randomized to one of two treatment sequences of\n      Zavesca with Florastor and Zavesca with Placebo of Florastor. Gastrointestinal tolerability\n      and PK endpoints, demographic, laboratory and safety testing, and AEs and SAEs will be\n      collected throughout the seventy-four day study."
        }, 
        "brief_title": "Two Period / Two Treatment Cross-over to Assess the Effect of Florastor\u00ae on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca\u00ae", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Diarrhea", 
        "condition_browse": {
            "mesh_term": "Diarrhea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent prior to any study-mandated procedure\n\n          -  Healthy male and female subjects aged between 18 and 55 years (inclusive) at\n             Screening\n\n          -  Women must have a negative serum pregnancy test at Screening and negative urine\n             pregnancy test at the first day of each treatment period and must use a reliable\n             method of contraception from Screening during the entire study and up to 30 days\n             after the last dose. Male subjects must agree to use reliable contraception\n             throughout the study and for 4 months after study drug discontinuation\n\n          -  Reliable methods of contraception for all subjects include the following:\n\n          -  Barrier type devices (e.g., male and female condom, diaphragm and contraceptive\n             sponges) used ONLY in combination with a spermicide\n\n          -  Intrauterine devices\n\n          -  Oral contraceptive agent\n\n          -  Depo-Provera (medroxyprogesterone acetate)\n\n          -  Levonorgestrel implants\n\n          -  Abstinence, the rhythm method, and contraception by the partner alone are NOT\n             reliable methods of contraception\n\n          -  A BMI of 18.5 to 30 kg/m2 (inclusive) at Screening\n\n          -  No clinically significant findings on the physical examination, laboratory\n             assessment, electrocardiogram (ECG), and vital signs at Screening\n\n        Exclusion Criteria:\n\n          -  Ingestion of any medication within 7 days prior to study enrollment (Day 1) except\n             contraceptives\n\n          -  Use of anti-diarrheal medications within 30 days prior to study enrollment (e.g.,\n             loperamide)\n\n          -  Use of oral probiotic supplements or S. boulardii within 30 days prior to study\n             enrollment\n\n          -  Use of oral antifungals or antibiotics within 8 weeks prior to study enrollment\n\n          -  History of yeast allergy\n\n          -  Current alcohol or drug dependence\n\n          -  Renal function impairment, (i.e., creatinine clearance [C Cr]<70 mL/min/1.73m2 as per\n             Cockroft-Gault)\n\n          -  History of GI distress including diarrhea (more than 2 loose stools per day, for 5 or\n             more days) within 30 days prior to study enrollment\n\n          -  History of irritable bowel syndrome, inflammatory bowel disease, or other disease\n             resulting in frequent or severe diarrhea\n\n          -  Lactose intolerance\n\n          -  Subjects on any specialized diet, including low carbohydrate diets Lactating,\n             pregnant women or women who plan to become pregnant during the course of the study\n\n          -  History of any neurological disease/symptom, e.g., convulsion\n\n          -  Loss of 500 mL or more of blood within 3 months prior to Screening\n\n          -  Positive results to HIV Ag/Ab, HBsAg or anti-HCV tests\n\n          -  Positive results from the HIV serology at Screening\n\n          -  History or clinical evidence of alcoholism or drug abuse within the 3-year period\n             prior to Screening\n\n          -  Excessive caffeine consumption, defined as >=5 cups of coffee a day or 800mg/day at\n             Screening\n\n          -  Smoking within 3 months prior to Screening and inability to refrain from smoking\n             during the course of the study\n\n          -  Any circumstances or conditions, which, in the opinion of the investigator, may\n             affect full participation in the study or compliance with the protocol\n\n          -  Legal incapacity or limited legal capacity at Screening\n\n          -  Unplanned weight loss defined as >5% within the past month or >=10% during the last 6\n             months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01822028", 
            "org_study_id": "AC-056-102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment A", 
                    "Treatment B"
                ], 
                "description": "Florastor\u00ae placebo. Zavesca\u00ae capsules dosed at 300 mg daily (one 100 mg capsule three times per day).", 
                "intervention_name": "Treatment A", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Florastor\u00ae placebo.", 
                    "Zavesca\u00ae capsules."
                ]
            }, 
            {
                "arm_group_label": [
                    "Treatment A", 
                    "Treatment B"
                ], 
                "description": "Florastor\u00ae capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).\nZavesca\u00ae capsules dosed at 300 mg daily (one 100 mg capsule three times per day).", 
                "intervention_name": "Treatment B", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Florastor\u00ae capsules.", 
                    "Zavesca\u00ae capsules."
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Miglustat"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "diarrhea", 
        "lastchanged_date": "April 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M9L 3A2"
                }, 
                "name": "BioPharma Services Inc."
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-center, Double-blind, Randomized, Placebo-controlled, Two Period / Two Treatment Cross-over Study to Assess the Effect of Florastor\u00ae (Saccharomyces Boulardii Lyo) on Gastrointestinal Tolerability, Safety, and Pharmacokinetics of Zavesca\u00ae (Miglustat) in Healthy Subjects", 
        "other_outcome": [
            {
                "description": "Plasma PK parameters will be derived by non-compartmental analysis of the concentration-time profiles of miglustat following the last dose at end of Periods 1 and 2. The area under the plasma concentration-time curve during a dosing interval (AUCt). The maximum plasma concentration (Cmax).  The time to reach maximum plasma concentration (tmax).", 
                "measure": "PHARMACOKINETIC ENDPOINTS", 
                "safety_issue": "No", 
                "time_frame": "day 16 and day 44"
            }, 
            {
                "description": "Treatment-emergent adverse events (TEAEs) up to 48 hours after the last study drug dose in each treatment period. Leading to the premature discontinuation of study drug. Treatment-emergent SAEs up to 48 hours after the last study drug dose in each treatment period. Change from baseline to EOT in body weight and vital signs blood pressure (BP) and heart rate (HR).", 
                "measure": "GENERAL TOLERABILITY/SAFETY ENDPOINTS, OTHER THAN GASTRO-INTESTINAL EVENTS", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to end of study (day 74)"
            }
        ], 
        "overall_official": {
            "affiliation": "Actelion", 
            "last_name": "Chad McQueen, PharmD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Ethics Review Committee", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Total number of days of diarrhea defined as 3 or more loose stools within a 24-hour period (WHO criteria) that meet the criteria of Bristol Stool Score 6-7.", 
            "measure": "GASTROINTESTINAL TOLERABILITY ENDPOINTS", 
            "safety_issue": "Yes", 
            "time_frame": "baseline to end of study (day 74)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01822028"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of consecutive days of diarrhea defined as 3 or more loose stools (WHO criteria) within consecutive 24-hour periods that meet the criteria of Bristol Stool Score of 6-7.", 
            "measure": "GASTROINTESTINAL TOLERABILITY ENDPOINTS", 
            "safety_issue": "Yes", 
            "time_frame": "baseline to end of study (day 74)"
        }, 
        "source": "Actelion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Actelion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}